For example, the incidence of endometrial cancer in MSH6 pathogenic variant carriers is as high as that in MLH1 and MSH2 pathogenic variant carriers,4 and the risk is much higher than in PMS2 pathogenic variant carriers. Here, MSH6 is linked to endometrial cancer.